NCT00744146View on ClinicalTrials.gov

First Time in Human Study of Protexia

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2009

Conditions
Intervention for Nerve Agent Exposure
Interventions
BIOLOGICAL

Protexia

Single 50 mg IM dose

BIOLOGICAL

Protexia

Single 100 mg dose

BIOLOGICAL

Protexia

Two 250 mg doses, IM, one at Day 1 and one at Day 72

BIOLOGICAL

Protexia

Single 500 mg dose, IM

BIOLOGICAL

Protexia

Single 750 mg dose, IM

Trial Locations (1)

66211

Quinitles Phase I Services, Overland Park

Sponsors

Lead Sponsor

PharmAthene, Inc.
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Quintiles, Inc.

INDUSTRY

collaborator

QPS Holdings LLC

INDUSTRY

lead

PharmAthene, Inc.

INDUSTRY

NCT00744146 - First Time in Human Study of Protexia | Biotech Hunter | Biotech Hunter